SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-24-000253
Filing Date
2024-02-15
Accepted
2024-02-15 08:10:27
Documents
15
Period of Report
2024-02-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALNYLAM PHARMACEUTICALS, INC. 8-K a53896787.htm   iXBRL 8-K 27789
2 EXHIBIT 99.1 a53896787ex99_1.htm EX-99.1 582635
  Complete submission text file 0001157523-24-000253.txt   783990

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alny-20240215.xsd EX-101.SCH 3863
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20240215_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20240215_pre.xml EX-101.PRE 16043
16 EXTRACTED XBRL INSTANCE DOCUMENT a53896787_htm.xml XML 4253
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 24642207
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)